Publications by authors named "Amelie Wickmann"
Cost Eff Resour Alloc
March 2024
Article Synopsis
- Triple-negative breast cancer (TNBC) accounts for 10-20% of breast cancer cases, leading to increased healthcare costs that necessitate health-economic evaluations to assess treatment options.
- The research analyzed the cost-benefit ratio of approved TNBC treatments in Germany using an efficiency frontier approach, focusing on costs and clinical benefits like median overall survival (mOS) and health-related quality of life (HRQoL).
- Findings showed that vinorelbine is the most cost-effective treatment, followed by sacituzumab-govitecan, with specific data on treatment costs and overall survival metrics reported for each therapy, guiding healthcare decision-makers in treatment choices.
